A
Alcista
Alcista · 25%RANI
$0.49
Precio del escenario
$0.516
-0.051 (-9.88%)Al cierre
Loading chart…
- Máximo
- 0.584
- Apertura
- 0.584
- Precio medio ponderado por volumen
- 0.54
- Volumen
- 697.75K
- Capitalización
- 103.64M
- Mínimo
- 0.510
- Importe
- 374.50K
- EV/EBITDA, TTM
- -2.36
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
Análisis de IA of Rani Therapeutics Holdings Inc (RANI)
VenderRani Therapeutics Holdings Inc is not a good buy right now due to its current price of $0.5518, which is close to its 52-week low of $0.55, and an extremely low RSI of 17.633 indicating oversold conditions. The company has reported a net loss of $8.4 million for Q2 2026, and its stock has seen a year-to-date decline of 59.43%.
Métricas de valoración
El PER previsto actual de Rani Therapeutics Holdings Inc (RANI) es 0.00, frente a su media de 5 años de -4.54.
Escenarios de precio de Alphio AI para RANI
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
9.508-27NASDAQ.COMRani Therapeutics Reports Q2 2026 Financial Results with Key Developments
5.007-31GlobenewswireRani Therapeutics Appoints New Head of Strategy
9.007-15NASDAQ.COMRani Therapeutics Reports Positive Initial Data for RT-114
7.507-10NASDAQ.COMRani Therapeutics Partners with PegBio for R&D Collaboration
5.006-30NASDAQ.COMRani Therapeutics Appoints New CFO Nicholas Maestas
Preguntas frecuentes sobre RANI, respondidas por Alphio AI
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Rani Therapeutics Holdings Inc is not a good buy right now due to its current price of $0.5518, which is close to its 52-week low of $0.55, and an extremely low RSI of 17.633 indicating oversold conditions. The company has reported a net loss of $8.4 million for Q2 2026, and its stock has seen a year-to-date decline of 59.43%.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.